Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIMER: Letrozole, Palbociclib, and SBRT in Metastatic ER+ Breast Cancer
NCT04563507Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2020
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Progression-Free Survival at 36 months. Started Nov 2020; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04563507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563507.